Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

Young Kwang Chae,Christos Vaklavas,Heather H. Cheng,Fangxin Hong,Lyndsay Harris,Edith P. Mitchell,James A. Zwiebel,Lisa M. McShane,Robert Gray,Shuli Li,S. Percy Ivy,Sherry S. Ansher,Stanley R. Hamilton,Paul M. Williams,James V. Tricoli,Carlos L. Arteaga,Barbara A. Conley,Peter J. O’Dwyer,Alice P. Chen,Keith T. Flaherty

Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

2018

2503Background: MATCH is a histology-agnostic signal finding trial targeting pathways in cancer. AZD4547 is a selective inhibitor of the fibroblast growth factor receptor (FGFR) 1-3 kinases. Method...

Keywords:

Fibroblast growth factor receptor
Pathology
Cancer research
Medicine
Phases of clinical research
in patient
Kinase
Cancer
molecular analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations